Overview

Spironolactone Therapy in Chronic Stable Right HF Trial

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and mechanistic effects of spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity and right heart function and remodeling in patients with chronic right heart failure.
Phase:
Phase 4
Details
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Treatments:
Mineralocorticoid Receptor Antagonists
Spironolactone